CXCL10 and lung carcinoma: Genetical or pharmacologic inhibition of KDM4C activated CXCL10 transcription by increasing the recruitment of the activated histone H3K36me3 at the CXCL10 promoter, which in turn increased the proliferation, migration, and activation of CD8+ T cells and delayed exhaustion in these cells in lung cancer.